317: Ignite Session 6B

Presentations:

• 2:00 PM – 2:05 PM Eastern Time

  Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
  

  Ignite Speaker: Marinella Govoni, PhD – MSD
• 2:05 PM – 2:10 PM Eastern Time

  Adherence to Early DMARD Strategies in Newly Diagnosed RA Patients Seen in Routine Care: Results from the Canadian Early Arthritis Cohort Study
  

  Ignite Speaker: Janet Pope, MD, FRCPC, MPH – University of Western Ontario
• 2:10 PM – 2:15 PM Eastern Time

  Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial
  

  Ignite Speaker: Jin Kyun Park, MD – Seoul National University College of Medicine
• 2:15 PM – 2:20 PM Eastern Time

  Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlled ARCTIC REWIND Trial
  

  Ignite Speaker: Siri Lillegraven, MD, PhD, MPH – Diakonhjemmet Hospital
• 2:20 PM – 2:25 PM Eastern Time

  Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial
  

  Ignite Speaker: Wendy Walrabenstein, MA – Amsterdam UMC
• 2:25 PM – 2:30 PM Eastern Time

  Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
  

  Ignite Speaker: Sofie Falkenløve Madsen, MSc – University of Copenhagen / Nordic Bioscience
• 2:30 PM – 2:35 PM Eastern Time

  Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
  

  Ignite Speaker: Arnd Kleyer, MD – University Hospital Erlangen
• 2:35 PM – 2:40 PM Eastern Time

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs
  

  Ignite Speaker: Alan J. Kivitz, MD – Altoona Center for Clinical Research
• 2:40 PM – 2:45 PM Eastern Time

  Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
  

  Ignite Speaker: Yasmin Khader, MD – University of Toledo